Galantamine hydrobromide - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for galantamine hydrobromide and what is the scope of freedom to operate?
Galantamine hydrobromide
is the generic ingredient in three branded drugs marketed by Aurobindo Pharma, Barr, Impax Labs, Norvium Bioscience, Sun Pharm, Watson Labs, Janssen Pharms, Hikma, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Rx, Dr Reddys Labs Ltd, Heritage Pharma, Mylan, Sandoz, Yabao Pharm, and Zydus Pharms Usa Inc, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.There are twelve drug master file entries for galantamine hydrobromide. Thirteen suppliers are listed for this compound. There are three tentative approvals for this compound.
Summary for galantamine hydrobromide
US Patents: | 0 |
Tradenames: | 3 |
Applicants: | 17 |
NDAs: | 22 |
Drug Master File Entries: | 12 |
Finished Product Suppliers / Packagers: | 13 |
Raw Ingredient (Bulk) Api Vendors: | 100 |
Clinical Trials: | 22 |
Drug Prices: | Drug price trends for galantamine hydrobromide |
What excipients (inactive ingredients) are in galantamine hydrobromide? | galantamine hydrobromide excipients list |
DailyMed Link: | galantamine hydrobromide at DailyMed |
Recent Clinical Trials for galantamine hydrobromide
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vanderbilt University Medical Center | Phase 1 |
Duke University | Phase 4 |
Ortho-McNeil Neurologics, Inc. | Phase 4 |
Generic filers with tentative approvals for GALANTAMINE HYDROBROMIDE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 12MG | TABLET; ORAL |
⤷ Sign Up | ⤷ Sign Up | 8MG | TABLET; ORAL |
⤷ Sign Up | ⤷ Sign Up | 4MG | TABLET; ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for galantamine hydrobromide
Drug Class | Cholinesterase Inhibitor |
Mechanism of Action | Cholinesterase Inhibitors |
Medical Subject Heading (MeSH) Categories for galantamine hydrobromide
Anatomical Therapeutic Chemical (ATC) Classes for galantamine hydrobromide
Paragraph IV (Patent) Challenges for GALANTAMINE HYDROBROMIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RAZADYNE ER | Extended-release Capsules | galantamine hydrobromide | 16 mg and 24 mg | 021615 | 1 | 2006-03-11 |
RAZADYNE ER | Extended-release Capsules | galantamine hydrobromide | 8 mg | 021615 | 1 | 2006-03-02 |
RAZADYNE | Tablets | galantamine hydrobromide | 4 mg, 8 mg and 12 mg | 021169 | 14 | 2005-02-28 |
US Patents and Regulatory Information for galantamine hydrobromide
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharm | GALANTAMINE HYDROBROMIDE | galantamine hydrobromide | CAPSULE, EXTENDED RELEASE;ORAL | 090178-002 | Feb 2, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Watson Labs | GALANTAMINE HYDROBROMIDE | galantamine hydrobromide | CAPSULE, EXTENDED RELEASE;ORAL | 079028-001 | Dec 15, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Chartwell Rx | GALANTAMINE HYDROBROMIDE | galantamine hydrobromide | TABLET;ORAL | 077587-001 | Jul 9, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for galantamine hydrobromide
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Pharms | RAZADYNE ER | galantamine hydrobromide | CAPSULE, EXTENDED RELEASE;ORAL | 021615-002 | Apr 1, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Janssen Pharms | RAZADYNE | galantamine hydrobromide | TABLET;ORAL | 021169-002 | Feb 28, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Janssen Pharms | RAZADYNE ER | galantamine hydrobromide | CAPSULE, EXTENDED RELEASE;ORAL | 021615-001 | Apr 1, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.